Cell line · CVCL_0527
Papers80
1 to 20 of 80
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| αvβ3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PAX3 Regulatory Signatures and Gene Targets in Melanoma Cells. | Genes (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TRPM8 levels determine tumor vulnerability to channel agonists. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HTS384 NCI60: The Next Phase of the NCI60 Screen. | Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators. | Sci Adv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression. | NAR Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of Prostate Cancer. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| GABA Regulates Electrical Activity and Tumor Initiation in Melanoma. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identifying the Transcriptional Drivers of Metastasis Embedded within Localized Melanoma. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. | Nat Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Generation and Validation of an Anti-Human PANK3 Mouse Monoclonal Antibody. | Biomolecules | 2022 | Its Methods give the RRID and name the line | PubMed | |
| AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. | Cell | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0527/papers